DAB2: A Protein Involved in Alzheimer's Disease and Pain Perception

Target Name: DAB2

NCBI ID: G1601

DAB2

DAB2: A Protein Involved in Alzheimer's Disease and Pain Perception

DAB2 (DAB2 variant 2) is a protein that is expressed in the brain and is involved in the development and progression of various neurological disorders, including Alzheimer's disease. The study of DAB2 and its potential as a drug target has generated a lot of interest in recent years.

DAB2 is a transmembrane protein that is characterized by its extracellular domain, which is composed of a variety of domains including an N-terminus, a T-terminus, and a C-terminus. The N-terminus of DAB2 contains a unique farnesylated cysteine residue, which is important for its stability and functions in the brain. The T-terminus of DAB2 contains a variable region that is involved in its interaction with other proteins. The C-terminus of DAB2 contains a conserved GXXGXXG motif, which is commonly found in proteins that are involved in intracellular signaling.

DAB2 is involved in a number of different signaling pathways, including the regulation of neurotransmitter release, the modulation of pain perception, and the regulation of synaptic plasticity. It is also involved in the development and progression of various neurological disorders, including Alzheimer's disease.

One of the most promising aspects of DAB2 is its potential as a drug target. The farnesylated cysteine residue in the N-terminus of DAB2 is a target for small molecules that have been shown to have neuroprotective effects. For example, studies have shown that farnesylated cysteine is modified by the neurotransmitter dopamine, which is involved in the regulation of mood, motivation, and reward. By modifying the farnesylated cysteine residue of DAB2, it may be possible to develop drugs that have neuroprotective effects against the development and progression of Alzheimer's disease.

In addition to its potential as a drug target, DAB2 is also a biomarker for the diagnosis and progression of Alzheimer's disease. The levels of DAB2 have been shown to be decreased in the brains of individuals with Alzheimer's disease, and studies have shown that increasing the levels of DAB2 can protect against the development and progression of the disease. This suggests that DAB2 may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

DAB2 is also involved in the regulation of pain perception, which is a complex process that is influenced by the interplay of many different factors, including the activity of pain modulators and the regulation of neurotransmitter release. Studies have shown that DAB2 is involved in the regulation of pain perception, and that changes in its expression levels can affect the intensity and persistence of pain. This suggests that DAB2 may be a useful target for the development of pain medications that are effective in treating a wide range of pain conditions.

In conclusion, DAB2 is a protein that is involved in the development and progression of various neurological disorders, including Alzheimer's disease. Its farnesylated cysteine residue and conserved GXXGXXG motif make it a promising target for small molecules that have neuroprotective effects. In addition, DAB2 is also a biomarker for the diagnosis and progression of Alzheimer's disease, and its involvement in the regulation of pain perception suggests that it may be a useful target for the development of pain medications. Further research is needed to fully understand the role of DAB2 in the development and treatment of Alzheimer's disease and other neurological disorders.

Protein Name: DAB Adaptor Protein 2

Functions: Adapter protein that functions as clathrin-associated sorting protein (CLASP) required for clathrin-mediated endocytosis of selected cargo proteins. Can bind and assemble clathrin, and binds simultaneously to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and cargos containing non-phosphorylated NPXY internalization motifs, such as the LDL receptor, to recruit them to clathrin-coated pits. Can function in clathrin-mediated endocytosis independently of the AP-2 complex. Involved in endocytosis of integrin beta-1; this function seems to redundant with the AP-2 complex and seems to require DAB2 binding to endocytosis accessory EH domain-containing proteins such as EPS15, EPS15L1 and ITSN1. Involved in endocytosis of cystic fibrosis transmembrane conductance regulator/CFTR. Involved in endocytosis of megalin/LRP2 lipoprotein receptor during embryonal development. Required for recycling of the TGF-beta receptor. Involved in CFTR trafficking to the late endosome. Involved in several receptor-mediated signaling pathways. Involved in TGF-beta receptor signaling and facilitates phosphorylation of the signal transducer SMAD2. Mediates TFG-beta-stimulated JNK activation. May inhibit the canoniocal Wnt/beta-catenin signaling pathway by stabilizing the beta-catenin destruction complex through a competing association with axin preventing its dephosphorylation through protein phosphatase 1 (PP1). Sequesters LRP6 towards clathrin-mediated endocytosis, leading to inhibition of Wnt/beta-catenin signaling. May activate non-canonical Wnt signaling. In cell surface growth factor/Ras signaling pathways proposed to inhibit ERK activation by interrupting the binding of GRB2 to SOS1 and to inhibit SRC by preventing its activating phosphorylation at 'Tyr-419'. Proposed to be involved in modulation of androgen receptor (AR) signaling mediated by SRC activation; seems to compete with AR for interaction with SRC. Plays a role in the CSF-1 signal transduction pathway. Plays a role in cellular differentiation. Involved in cell positioning and formation of visceral endoderm (VE) during embryogenesis and proposed to be required in the VE to respond to Nodal signaling coming from the epiblast. Required for the epithelial to mesenchymal transition, a process necessary for proper embryonic development. May be involved in myeloid cell differentiation and can induce macrophage adhesion and spreading. May act as a tumor suppressor

The "DAB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets